AbbVie’s Q2 earnings showed strong top-line growth—revenue up 10% to $17B, net income up 23%—but missed EPS expectations at $3.65, sparking market jitters. Key divisions like immunology (up 15%) and neuroscience (up 20%) drove gains, while oncology dipped 2%. The real concern? A downward revision to full-year EPS guidance, now projected between $13.87 and $14.07—below Wall Street’s $14.12 estimate—blamed on the recent Apogee Therapeutics acquisition. Though investors reacted negatively, some analysts see this as a short-term hiccup for a company with a powerhouse pipeline, suggesting long-term confidence may still hold.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
